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Abstract Various oligosaccharides containing galactose(s)
and one glucosamine (or N-acetylglucosamine) residues
with β1–4, α1–6 and β1–6 glycosidic bond were synthe-
sized; Galβ1–4GlcNH2, Galα1–6GlcNH2, Galα1–
6GlcNAc, Galβ1–6GlcNH2, Galβ1–4Galβ1–4GlcNH2 and
Galβ1–4Galβ1–4GlcNAc. Galα1–6GlcNH2 (MelNH2) and
glucosamine (GlcNH2) had a suppressive effect on the
proliferation of K562 cells, but none of the other saccharides
tested containing GlcNAc showed this effect. On the other
hand, the proliferation of the human normal umbilical cord
fibroblast was suppressed by none of the saccharides other
than GlcNH2. Adding Galα1–6GlcNH2 or glucosamine to
the culture of K562 cell, the cell number decreased strikingly
after 72 h. Staining the remaining cells with Cellstain
Hoechst 33258, chromatin aggregation was found in many
cells, indicating the occurrence of cell death. Furthermore, all
of the cells were stained with Galα1–6GlcNH-FITC
(MelNH-FITC). Neither the control cells nor the cells
incubated with glucosamine were stained. On the other hand,
when GlcNH-FITC was also added to cell cultures, some of
them incubated with Galα1–6GlcNH2 were stained. The
difference in the stainability of the K562 cells by Galα1–
6GlcNH-FITC and GlcNH-FITC suggests that the intake of
Galα1–6GlcNH2 and the cell death induced by this saccha-
ride is not same as those of glucosamine. The isolation of the
Galα1–6GlcNH2 binding protein was performed by affinity
chromatography (melibiose-agarose) and LC-MS/MS, and
we identified the human heterogeneous ribonucleoprotein
(hnRNP) A1 (34.3 kDa) isoform protein (30.8 kDa). The
hnRNPA1 protein was also detected from the eluate(s) of the
MelNH-agarose column by the immunological method (anti-
hnRNP-A1 and HRP-labeled anti-mouse IgG (γ) antibodies).
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It has been reported that glucosamine (GlcNH2) is an amino
monosaccharide occurring in connective and cartilage
tissues of humans and other animals [1–3]. It is well
known that this amino sugar is a precursor substance of
glycosaminoglycans [4], and that it has an effect on nitric
oxide synthesis [5] and a reparation effect on arthrodial
cartilage such as in case of osteoarthritis [6–8]. Further-
more, it has been suggested that glucosamine benefited
some patients with knee osteoarthritis and that it aided
wound healing [9, 10]. Quastel and Cantero observed that
GlcNH2 injection into mice with tumor sarcoma 37
inhibited the tumor growth, and suggested that administra-
tion of GlcNH2 might divert adenosine triphosphate (ATP)
activity to affect the rates of the metabolic paths involved in
tumor proliferation [11]. Molnar and Bekesi reported that
addition of GlcNH2 or mannosamine (ManNH2) in Ehrlich
ascites carcinoma and Sarcoma 180 ascites tumor cells in
vitro provoked striking cytoplasmic and nuclear changes,
including vacuolization of the cytoplasm and various
degrees of disintegration [12]. Moreover, they found that
continuous vein infusion with glucosamine resulted in a
high rate of tumor regression in rats with i.m. Walker 256
carcinosarcoma [13]. Ichikawa et al. reported that incuba-
tion of mastocytoma P-815 cells with 5 mM glucosamine
resulted in a marked inhibition of growth and significant
reduction of cellular uptake and oxidation of glucose and
cellular level ATP, and that glucosamine also reduced the
uridine nucleotides and accumulated UDP-GlcNAc [14].
It has also been reported that a melibiose-binding protein
composed of −58, 32, 26 kDa polypeptides was isolated
from human spleen, and the protein was mainly anti-αGal
antibody and it preferred Galα1–6 to Galα1–3 [15].
Galectin-1 (14 kDa), which is a generously β-galactose
binding protein, was isolated from bovine heart (BHL-14)
and reexamined regarding the binding specificity against
saccharides, and it was observed that terminal α-linked
galactose, rather than β-galactose in N-acetyllactosamine
was the ligand for the galectin-1 [16]. Moreover, it is
supposed that galectin-1 (β-galactose binding protein),
which was expressed by stromal cells in human thymus
and lymph nodes, induced apoptosis of activated human T-
cells and human T-leukemia cell lines, and that galectin-1,
which induced apoptosis, required expression of CD45 [17].
McReynolds et al. showed that human immunodeficiency
virus (HIV-1) recombinant gp 120 (rgp 120) recognized
non-natural glycosphingolipids, cellobiosyl and melibiosyl
ceramides but not those lacking a lipid component [18].
We have taken notice of the various functions of
glucosamine, such as its anti-inflammatory and other
properties in humans and other animals, and have been
furthering the development of novel functional oligosac-
charides. Thus, we synthesized several oligosaccharides
having a glucosamine residue at the reducing terminal,
using several α- and β-galactosidases. Moreover, we
examined their effects on some human cancer and normal
cells, and we attempted to identify Galα1–6GlcNH2
binding protein from K562 cells.
Materials and methods
Saccharides
Lactosamine (LacNH2, Galβ1–4GlcNH2), allolactosamine
(AlloLacNH2, Galβ1–6GlcNH2), MelNAc (Galα1–
6GlcNAc), MelNH2 (Galα1–6GlcNH2), galactosyl-N-
acetyllactosamine (GalLacNAc, Galβ1–4Galβ1–4GlcNAc)
and galactosyllactosamine (GalLacNH2, Galβ1–4Galβ1–
4GlcNH2) were synthesized by reverse reactions of α- and
β-galactosidases of bacteria, Aspergillus niger and
Aspergillus oryzae, respectively (PT No. 2004–352672
and 2004–352673). N-acetyllactosamine (LacNAc, Galβ1–
4GlcNAc), N-acetyl-allolactosamine (AlloLacNAc, Galβ1–
6GlcNH2) and chito oligosaccharides (bi-, tri-, tetra- and
penta-: GlcNH2[β1–4GlcNH2]1~4) were supplied by Yaizu
Suisankagaku Ind. Co. (Yaizu, Japan). Each oligosac-
charide was dissolved in the 0.05 M 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), pH 7.0,
buffer containing 0.15 M NaCl, and filtrated (pore size
0.45 μm, Advantec Co., Tokyo) to sterilize. Fluorescein
isothiocyanate-labeled Galα1–6GlcNH2 and GlcNH2
(MelNH-FITC and GlcNH-FITC) were synthesized by us.
Briefly, reaction mixtures contained equal moles of each
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saccharide and FITC in 0.025 M phosphate buffer, pH 9.0,
and were incubated for 30 min at room temperature and
purified by thin layer chromatography (TLC) using
chloroform/methanol (70/30) developmental solution.
After TLC development, the synthesized MelNH- and
GlcNH-FITC were isolated and recovered. Cellstain Hoechst
33258 (H33258) was purchased from Sigma-Aldrich Co.
(St. Louis, MO, USA). Antibodies, mouse monoclonal anti-
hnRNP-A1 antibody and horse radish peroxidase (HRP)-
labeled goat anti-mouse IgG(γ), and polyvinylidene fluoride
(PVDF) membrane for immunological detection were pur-
chased from KPL (Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA), Sigma and Millipore (Bedford,
MA, USA), respectively. Other chemicals of analytical grade
were obtained from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan) and Sigma.
Cell culture
Cells (human leukemia cell, K562 cells; human normal
umbilical cord fibroblast (HUC-F2) cells) were purchased
from the Riken Cell Bank (Tsukuba, Japan). Cell culture
was carried out in Ham F-12 medium [Sigma; containing
10% fetal bovine serum (FBS)] for K562 cells and in
αMEM (alpha minimum essential medium, containing 10%
FBS, Sigma) for HUC-F2 cells in a 5% CO2 humidified air
environment for 3–4 days at 37°C using Petri dishes (70×
15 mm). Cells were collected by centrifugation at
1,000 rpm for 10 min, carefully aspirated and resuspended
with fresh medium. In the case of HUC-F2 cell culture,
confluent cells were treated with 0.25% trypsin-0.2%
ethylenediaminetetraacetic acid (EDTA) in medium (Invi-
trogen, Co., Carlsbad, CA. USA), carefully shaken for 5–
10 min at 37°C, centrifuged at 1,000 rpm for 10 min and
washed with αMEM medium (10% FBS). Cells were
suspended again in fresh medium and the number of cells
was adjusted to 1.0∼ 1.7×105 cells/ml.
Suppression experiment of cell proliferation by saccharides
The suppression experiments of the cell proliferation were
carried out using cells (K562 and HUC-F2) and saccharides
as inhibitors in triplet. The cell culture medium (0.36 ml) of
K562 was added to a 24-well plate, and incubated with 5∼
10 mM saccharides using 50 and 100 mM as their stock
solutions for 24∼ 72 h in the CO2 incubator. As a blank
control, an aliquot of 50 mM HEPES buffered saline
(pH 7.0), in place of saccharide, was added to the cell
culture. After incubation, the cell number was counted
using a cell counting chamber, except for the injured and
shrunk cells, under the microscope at ×100∼ 200 magni-
fications, without cell staining by dye. After incubation of
HUC-F2 with or without saccharides, the cell culture was
aspirated carefully and 0.2 ml of 0.25% trypsin-0.2%
EDTA was added to each well. Careful shaking was
performed as described above, and fresh medium (0.2 ml)
was added and the cell number was counted in the same
manner as described above.
Cell staining with Cellstain Hoechst 33258, MelNH-FITC
and GlcNH-FITC
In order to determine cell death, we observed nuclear
chromatin aggregates of cultured cells with or without
saccharides (GlcNH2 or MelNH2) using Cellstain Hoechst
33258 fluorescence dye, H33258, (2 mM solution in
50 mM Tris-HCl, pH 7.4, buffered saline). After staining
cells (15 μl of suspension) with dye (1 μl) about 5 min at
room temperature, aliquots (5∼ 10 μl) of cell suspension
were dropped on slide glass and covered with cover glass
without washing with fresh medium. MelNH-FITC and
GlcNH-FITC fluorescent dyes (2 mM solution in 50 mM
Tris-HCl, pH 7.4, buffered saline) were used for investiga-
tion of stainability of the cells which were cultured with
oligosaccharide, using the same procedure as described
above. The fluorescent cells were observed by fluorescent
microscope at 346 nm for H33258 and 492 nm for MelNH-
and GlcNH-FITC, respectively. Each cell sample dyed with
H33258 was also observed optically.
Extraction of melibiose binding protein
K562 cells (about 5×109) cultured without any saccharide
were collected by centrifugation at 1,000 rpm for 10 min at
room temperature, washed thoroughly with 10 mM Tris-
HCl buffer, pH 7.4, containing 0.15 M NaCl and exposed
to 2 ml of 0.1% Triton X-100 and 100 mM melibiose in the
same buffer. After gentle shaking by magnetic stirrer, the
cell lysate was sonicated at 1.5 kW for 2 min at 4°C and
centrifuged at 12,000 rpm for 30 min at 4°C. The
supernatant was collected and the precipitate was washed
with the same buffer. The supernatants were mixed and
dialyzed two times against 500 ml of the same Tris-HCl
buffer without melibiose.
Affinity chromatography
The dialyzed sample was applied to affinity column
chromatography at 4°C, and the melibiose-binding mate-
rial(s) was isolated, using a modification of the method of
Sharma et al. [15]. Briefly, the cell extract was applied to
the immobilized melibiose (Seikagaku Co. Tokyo) column,
1.0×5 cm, equilibrated with 10 mM Tris-HCl buffer,
pH 7.4, containing 0.1% Triton X-100, 1 mM CaCl2 and
1 mM MgCl2, and the column was washed with about
100 ml of the same buffer. The melibiose-binding material
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(s) was eluted with 0.4 M melibiose in the same buffer, and
each fraction (1.4 ml) was collected. The elutant was used
for the following experiments.
Furthermore, another affinity chromatography (MelNH-
agarose), in which the column was made by us using
HiTrap™ NHS-activated HP column (1 mll; GE Health-
care, Uppsala, Sweden), was done as described above
except for elution by 0.1 M MelNH2. Each sample, crude
extract, unbound fraction and bound fraction (concentrated
to about ten-fold), was tested for detection of the hnRNP
A1 by immunological method.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
An aliquot (15 μl) of each fraction eluted from the affinity
(melibiose-) column was treated with the loading buffer
(Invitrogen) without the SH-reagent, 2-mercaptoethanol
(2 ME), for 3 min at 90°C and applied to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE;
NuPAGE, 10% gel, Invitrogen) using NuPAGE MOPS
buffer in accordance with the manufacturer’s instructions.
After electrophoresis, the slab gel was stained with silver
staining (Daiichi Pure Chemicals Co. Ltd. Tokyo). The
fractions, which contained melibiose binding material(s)
were pooled and concentrated by Amicon Ultra-4 (Millipore,
Co. Bedford, MA, USA) at 3,500 rpm for 40∼ 60 min at 4°C.
A part (15 μl) of the concentrated sample was loaded again
on NuPAGE under reducing and non-reducing conditions for
3 min at 90°C and the gel was stained with silver staining.
LC-MS/MS analysis of the melibiose binding protein
In order to identify the MelNH2 binding protein, the sample
(30 μl) described above and acrylamide (20 μmol) were
mixed and treated for 3 min at 95°C. The mixture was
applied on a stacking gel and the cysteine residues were
alkylated with acrylamide during SDS-PAGE [19]. After
electrophoresis and silver staining, the corresponding band
on the gel was cut out and digested with trypsin. The triptic
peptides were subjected to LC-MS/MS analysis using API
QSTAR Pulsar (I) hybrid mass spectrometer (Applied
Biosystem, Foster City, CA, USA) with a nano-liquid
chromatography (DiNa, KYA TECH Corporation, Tokyo,
Japan). The nano-LC was carried out using Magic C18
column (0.2 mm ID×50 mm) and peptides were eluted with
0.1% formic acid and 0.1% formic acid 90% CH3CN.
Protein on SDS-PAGE was identified with LC-MS/MS
using Mascot search engine (Matrix Science, UK) and
NCBI database.
Aliquot (10 μl) of each sample (crude extract, unbound
and bound fractions), which was obtained from MelNH-
agarose affinity chromatography was blotted on PVDF
membrane. Membrane strips were treated or not treated
with 0.3% H2O2-methanol prior to immunostaining using
mouse anti-hnRNP A1 monoclonal antibody and HRP-
labeled goat anti-mouse IgG (γ) antibody.
Results
Suppressive effect of novel oligosaccharides on cancer
cell proliferation
Among the oligosaccharides and monosaccharides tested,
Galα1–6GlcNH2 (MelNH2) had the strongest suppressive
effect on the proliferation of K562 cells (Fig. 1A). GlcNH2
was also an effective suppressor, and other oligosac-
charides containing glucosamine (LacNH2, AlloLacNH2
and GalLacNH2), but not N-acetylglucosamine (GlcNAc,
LacNAc, AlloLacNAc and MelNAc), controlled on the




















































































Fig. 1 Effects of various saccharides on human leukemia K562 cell
proliferation (A) Each saccharide was added to the cell culture at
5 mM concentration. (B) Chito-oligosaccharide (di, tri, tetra and
penta: CH-2, CH-3, CH-4 and CH-5, 5 mM concentration) effect on
cell proliferation after 72 h. Data are shown as the mean ± SD. (n=3
for all saccharide samples). **p<0.01 compared with the control
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AlloLacNH2 and MelNH2 both have the 1–6 glycosidic
bond between galactose and GlcNH2 residues, the former
showed only a weak inhibitory effect on K562 cell
proliferation. As shown in Fig. 1B, chito-oligosaccharides
(chito-biose, chito-triose, chito-tetraose and chito-pentaose)
were tested for their influence on the cell proliferation, and
chito-biose (GlcNH2β1–4GlcNH2) seemed to be slightly
inhibitive against K562 cell proliferation. However, other
chito oligosaccharides (chito-triose~chito-pentaose) seemed
to have no effect on the cell proliferation.
Neutral saccharides (such as glucose, galactose, lactose
and melibiose) tested showed no influence on proliferation
of K562 cells (part of the data not shown).
On the other hand, when human normal umbilical cord
fibroblasts, HUC-F2 cells, were incubated with a series of
oligosaccharides, the cell proliferation was influenced only
by GlcNH2 (Fig. 2).
Mel and MelNH2 are structurally very similar, but their
effects on the K562 cells are quite different. The question
arises as to whether these saccharides share in part the same
metabolic pathway, such as through an interaction with
specific melibiose-binding protein(s). To clarify this, the
effect of preincubation with Mel against anti-proliferation
action of MelNH2 was examined using K562 cells (Fig. 3).
Mel moderately inhibited MelNH2 action; after 72 h
incubation the cell number increased about four-fold
(compare left and middle columns in Fig. 3). However,
simultaneous treatment of Mel and MelNH2 did not
increase the cell number (data not shown), suggesting that
they share the same binding molecule, at least in part.
Cell staining with Cellstain Hoechst 33258, MelNH-FITC
and GlcNH-FITC
In order to clarify the cell stainability with H33258,
MelNH-FITC and GlcNH-FITC fluorescent dyes, the
K562 cells were observed under the fluorescent microscope
after dyeing. As shown in Fig. 4, 1a, when the cells were
cultured for 24 h without any saccharide and stained with
H33258, most cells were of a good shape and dark blue.
Moreover, no cells showed any nuclear aggregation. With
MelNH-FITC, however, most of the cells did not show
staining and they were black under the fluorescent
microscope (Fig. 4, 1c). Incubation of cells with 5 mM
GlcNH2 or MelNH2 for 24 h showed that a few cells
were bright with H33258 staining. But most cells did not
show staining with MelNH-FITC (data not shown): thus
the situation was almost the same as the control
incubation for 24 h. The incubation for 72 h with no
specially added saccharide gave the result that several
cells were bright (H33258) and their nuclear chromatin
was detected to be aggregated (Fig. 4, 2a), but almost all
were not stained with MelNH-FITC (Fig. 4, 2c). Moreover,
the incubation of cells with 5 mM GlcNH2 for 72 h gave
the result that about half of them were brightly stained
with H33258 and their chromatin was aggregated, but
only several cells were greenish in the case of MelNH-
FITC staining, as shown in Fig. 4, 3a and 3c. On the other
hand, when cells were cultured with 5 mM MelNH2 for
72 h, all cells showed aggregated nuclear chromatin
(Fig. 4, 4a), and they were also stained with MelNH-FITC
(Fig. 4, 4c).
When cell staining with GlcNH-FITC was carried out





































Fig. 3 Inhibition against MelNH2 suppressive effect on K562 cell by
Mel The cell was cultured with 12.5 mM Mel for 1∼ 2 h prior to
addition of 5 mM MelNH2, and after 72 h incubation the remaining
cell was counted. Data are shown as the mean ± SD. (n=3 for all



























































Fig. 2 Effects of saccharides on the proliferation of human normal
HUC-F2 cells. Data are shown as the mean ± SD (n=3 for all
saccharide samples). **p<0.01 compared with the control
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among the cells incubated with MelNH2 more than half
were not stained (Fig. 5, 2c).
Furthermore, when any oligosaccharide (5 mM) having a
GlcNAc residue was added to the cell culture, chromatin
aggregation was observed to be only of the same grade as
that of the control (data not shown).
SDS-PAGE of the fraction eluted
from the melibiose–agarose column
Each fraction which was eluted from the Mel-conjugated
column was loaded on SDS-PAGE under non-reducing
























Fig. 4 K562 cell staining by Hoechst 33258 and MelNH-FITC Each
cell sample was stained with Hoechst 33258 and MelNH-FITC after
24 and 72 h cell incubation with or without saccharides (GlcNH2 and
MelNH2), and observed under the fluorescent microscopy (a and c).
Each cell sample (stained with H33258) was also observed optically
(b) at ×200 magnification. Bar, 100 μm
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shown). The fractions, Nos. 6∼ 9, were collected, concen-
trated to about 0.3 ml and applied again on SDS-PAGE. As
shown in Fig. 6, one main (76.0 kDa) and one minor
(48.0 kDa) band were detected under non-reducing con-
ditions, and one major (30.8 kDa) band was detected under
reducing conditions. Thus the Mel binding protein(s) was
effectively purified by one step affinity chromatography.
Identification of the MelNH2 binding protein
by LC-MS/MS analysis and immunological method
Sequences of several peptides which were obtained from
the 30.8 kDa protein band on the SDS-PAGE were
analyzed and determined by trypsin digestion and LC-MS/
MS analysis, and each peptide consisted of 12∼ 19 amino
acids (Fig. 7). From the result of sequences of peptides
hnRNP A1 (34.3 kDa) isoform protein (30.8 kDa) was
identified as a candidate with sequence coverage of 25% as
shown in Fig. 7.
As shown in Fig. 8, when the elutants from the MelNH-
agarose column were immunostained by anti-hnRNP A1
monoclonal and HRP-anti-mouse IgG (γ) antibodies on
PVDF membrane, the hnRNP A1 was only detected in the
Fig. 7 Human hnRNP A1 amino acid sequence The amino acid
sequence of human hnRNP A1 was determined by Buvoli et al. [28],
and was about 34.3 kDa. Amino acids sequences circled with squares












Fig. 5 Stainability of K562 cells with GlcNH-FITC after adding of
GlcNH2 and MelNH2 After 72 h incubation of cells with GlcNH2 and
MelNH2, cell samples were stained by GlcNH-FITC and were
observed optically (1a∼ 1c) and under fluorescent (2a∼ 2c)
microscopy at ×200 magnification. Bar, 100 μm










Fig. 6 SDS-PAGE of the Mel-
binding protein obtained from
the affinity chromatography
Lane NR: Sample was not
treated by reducing reagent.
Lane R: The same sample was
treated by two ME reducing
reagent. Standard proteins were
myosin (188 kDa), phos
phorylase B (97 kDa), glutamic
dehydrogenase (51 kDa),
carbonic anhydrase (33 kDa),
myoglobin blue (21 kDa) and
myoglobin red (19 kDa)
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fraction eluted with 0.1 M MelNH2 after sample blotting
and treating the membrane with 0.3% H2O2–methanol
(Fig. 8). However, the dark brown spots were also detected
on all untreated spots.
Discussion
We showed that novel synthesized oligosaccharides, espe-
cially MelNH2 (Galα1–6GlcNH2), had the strongest inhibi-
tory activity on the cancer cell proliferation of human
leukemia cells (K562), but not on normal cells (HUC-F2;
Figs. 1 and 2). Moreover, GlcNH2 monosaccharide was
also an inhibitor of the cancer and normal cells. Quastel and
Cantero have reported that daily injection of GlcNH2,
intraperitoneally, into mice with tumors showed suppressive
effect on the growth of the tumors, and they expected that
administration of GlcNH2 might divert ATP activity to
affect the rates of the metabolic paths involved in tumor
proliferation [11]. They also showed that the radioactive
intermediates found following the administration of
glucosamine-14C were GlcNAc-6P, GlcNAc-1P, GlcNH2–
6P, UDP-GlcNAc, UDP-GalNAc and sialic acid, and they
expected that glucosamine derivatives had a cytotoxic
effect on the tumors, which should be most sensitive to
glucosamine. Ichikawa et al. reported that incubation of
mastocytoma P-815 cells with 5 mM glucosamine resulted
in a marked inhibition of the cell growth [14]. They further
reported that the cellular uptake and oxidation of glucose
and the cellular level of ATP were significantly reduced by
addition of glucosamine, and that a diminishing of uridine
nucleotides and an accumulation of UDP-GlcNAc were
observed. In our study, addition of GlcNH2 to the K562 cell
culture decreased the cell numbers of the K562. Thus we
suppose that GlcNH2 should also divert ATP activity, and
that its derivatives should damage cancer cells. The precise
mechanism of the reduction of the cancer cells, however,
remains unclear.
On the other hand, the degree of suppressive activity of
MelNH2 against the K562 cell proliferation was higher than
that of GlcNH2, although the same concentrations of these
saccharides (5 mM each) were used for this examination.
Furthermore, the MelNH2 addition to the K562 cell culture
decreased the cell numbers to a greater degree than those of
other oligosaccharides which had GlcNH2 residue
(LacNH2, AlloLacNH2 and GalLacNH2), as shown in
Fig. 1A. These results suggest that it is unreasonable to
think that MelNH2 might be hydrolyzed to two mono-
saccharides (Gal and GlcNH2) and that the GlcNH2 residue
functions as an inhibitor against cancer cell proliferation.
Supposing this assumption is correct, the influence of
GlcNH2 on the K562 cells must be greater than that of
MelNH2. Thus we expect that the administration effects
of MelNH2 and GlcNH2 on the K562 cells indicate the
differences between their metabolic pathways in cancer
cells.
Furthermore, chito-disaccharide might have a slight inhib-
itory effect on K562 cells, but other chito-oligosaccharides
(tri-, tetra- and penta-) showed no suppressive affect on the
cell proliferation, indicating that chito-oligosaccharides were
neither taken up into the cell nor metabolized (Fig. 1B). It
seems quite likely that chito-disaccharide or other chito-
oligosaccharides could be neither hydrolyzed in the cell
culture systems nor absorbed on the cell surface.
The results of the preincubation examination of K562
cells with Mel prior to the incubation with MelNH2 showed
a moderate decrease in the anti-proliferation activity of
MelNH2. This suggests that the same receptor(s) against
MelNH2 and Mel is present on the cell (Fig. 3), and that the
former has a higher affinity than the latter.
After incubation of the K562 cell with MelNH2 or
GlcNH2, the cell was stained with H33258, MelNH-FITC
and GlcNH-FITC, as shown in Figs. 4, 1a~4c and 5. The
degree of stainability of the K562 cell changed with
progress of time and a drastic change seemed to occur
about 48 h incubation after. This suggests that the influence
of MelNH2 or GlcNH2 upon the K562 leukemia cells
increased slowly. After incubation for 72 h with MelNH2,
every cell was stained with these two fluorescence dyes
(H33258 and MelNH-FITC) and their nuclear chromatin
aggregations were identified as light blue ones (Fig. 4, 4a
and 4c). However, although GlcNH2 showed a suppressive
effect against the K562 cell proliferation, only half of the
cells were stained with H33258 after 72 h incubation and
the cells were not sufficiently stained by MelNH-FITC
Fig. 8 Detection of hnRNP A1 protein on the PVDF membrane by
immunological method Crude Ext.; K562 cell extract fraction, UBf;
unbound fraction to the MelNH-agarose column, Bf; bound fraction to
the same column, TR; Each sample was treated with 0.3% H2O2-
methanol at room temperature for 30 min in order to inactivate
endogenous peroxidase activities, NT; not treated with H2O2-methanol
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(Fig. 4, 3a and 3c). Furthermore, as described in these
figures, the brightly stained cells which showed nuclear
chromatin aggregation with H33258 were determined to
have shown cell death induced by these saccharides and
most cells died after MelNH2 addition (Fig. 4, 4a and 4c).
On the other hand, staining of the cells with GlcNH-FITC
showed a difference from that with MelNH-FITC (Figs. 4,
4 and 5), suggesting that there might be some uptake
pathways of these saccharides. Thus these results suggest
that the cell death pathway of K562 cells induced by
MelNH2 differs from that induced by GlcNH2 and that at
least some cell death pathways induced by saccharides
might be present. We hope that the MelNH2 and Mel
specific receptor protein(s) exists in/on the K562 cell
membrane and that the cell takes up and transport these
saccharides by this molecule(s).
We determined by LC-MS/MS analysis and immuno-
logical method that the Mel/MelNH2 binding protein is the
hnRNP A1 isoform, and that this protein had an apparent
molecular mass of 30.8 kDa on SDS-PAGE (Figs. 6, 7 and
8). Human hnRNP A1 is a single-stranded nucleic acid-
binding protein, which has many functions in various
aspects of mRNA maturation and in telomere length
regulation [20, 21]. On the other hand, Murzin et al. have
observed a novel folding motif in four different proteins,
which bind oligonucleotides or oligosaccharides: in nucle-
ase, anticodon binding domain of asp-tRNA synthetase and
B-subunits of heat-labile enterotoxin and verotoxin-1 (in
some enzymes and toxins) [22]. They called the OB-fold in
which a five-stranded β-sheet was coiled to form a closed
β-barrel. Moreover, the hnRNP protein is predicted to have
a very closely related motif and to bind to oligosaccharide
(e.g. lactose) as well as oligonucleotide [22, 23]. It was
shown that the hnRNP was shuttling between the nucleus
and the cytoplasm [24]. Celis et al. and LeStourgeon et al.
reported that there was a marked difference in the
concentration of hnRNP A1 between resting or dividing
cells and rapidly dividing cells [25, 26], and Xu et al.
demonstrated that levels of hnRNP A1 were elevated in
some cancers [27]. We observed that MelNH2 and GlcNH2
did not significantly influence the K562 cells, which had
been cultivating for about 6 months and that the division
speed decreased (data not shown), and that the human
normal cell (HUC-F2) was controlled by only GlcNH2 but
not MelNH2. We have carried out an experiment on the
influence of some saccharides on the human B cell derived
leukemia cell line (BALL cells), and found that the BALL
cells was also controlled with MelNH2, GlcNH2 and
alloLacNH2 (data not shown). We think that novel oligo-
saccharides containing amino-sugar (e. g. glucosamine) show
a certain effect on the leukemia cell lines in vitro. Thus we
suppose that a molelule having specific affinity against
MelNH2 appears in the K562 cells and that it is elevated on/
in the cancer cell membrane, and that MelNH2 taken into
cells disturbs the abilities of the hnRNP to mature mRNA
regulating telomere length or to perform other significant
function(s) for the cancer cell proliferation and survival.
Thus, although it is not clear how MelNH2 is taken into the
K562 cells, we hope that the MelNH2 binding protein
(hnRNP A1 isoform) plays important roles in transporting
MelNH2 into the cell nucleus via the cytoplasm. However,
the molecule which was expected to be the receptor on/in the
cell membrane was not detected in this study. This will be a
subject of our research in the near future.
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